TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
BerGenBio ASA ( (BRRGF) ) has provided an update.
Oncoinvent ASA has announced a fully underwritten rights issue to raise NOK 130 million, with the subscription price set below the current nominal value per share, necessitating a share capital reduction. This move aims to support the company’s ongoing clinical trials and strengthen its market position in the radiopharmaceutical sector.
The most recent analyst rating on (BRRGF) stock is a Buy with a NOK38.00 price target. To see the full list of analyst forecasts on BerGenBio ASA stock, see the BRRGF Stock Forecast page.
More about BerGenBio ASA
Oncoinvent is a clinical-stage biotechnology company focused on developing novel radiopharmaceutical therapies for cancer treatment. Their lead product, Radspherin®, targets micro-metastases in the peritoneum post-surgery using radium-224, offering a unique therapeutic approach with promising early clinical efficacy data.
Average Trading Volume: 110,225
Current Market Cap: NOK190.2M
Learn more about BRRGF stock on TipRanks’ Stock Analysis page.